PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

CLINICAL NEUROPATHOLOGY is a vital scholarly journal published by DUSTRI-VERLAG DR KARL FEISTLE, specializing in the domains of neurology, pathology, and their clinical applications. Established in 1982 and spanning through to its projected completion in 2024, this journal disseminates high-quality research that significantly contributes to the understanding of neurological disorders and their pathological underpinnings. While the journal currently operates under a traditional access model, its commitment to rigorous peer review ensures the publication of impactful findings, strengthening its foothold in the field, as evidenced by its Q3 quartile rankings in several categories, including Medicine (miscellaneous), Neurology, and Pathology and Forensic Medicine. Those engaged in clinical research and practice will find CLINICAL NEUROPATHOLOGY to be an essential resource for the latest advancements, trends, and discussions that shape the future of neurological pathology.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

NEUROGENETICS is a distinguished journal published by SPRINGER, focusing on the intersection of genetics and neuroscience. With its ISSN 1364-6745 and E-ISSN 1364-6753, this journal has been a vital resource in the fields of cellular and molecular neuroscience and genetics since its establishment in 1997. As of 2023, it is ranked Q3 in Cellular and Molecular Neuroscience and Q2 in both Genetics and Clinical Genetics, reflecting its growing influence and importance in these areas. Although not an open-access journal, it provides significant insights and research findings that contribute to advancing our understanding of genetic influences on neural function and disease. Based in Germany with an address at ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES, NEUROGENETICS serves as a crucial platform for researchers, professionals, and students alike to explore innovative studies that are essential for the future of neuroscience and genetics. With its continuous commitment to high-quality research, the journal aims to foster collaboration and knowledge dissemination among the scientific community.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

BRAIN PATHOLOGY, published by WILEY, is a leading journal in the fields of neurology, neuroscience, and pathology, recognized for its rigorous peer-review process and high-impact research contributions. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories, BRAIN PATHOLOGY maintains a prominent status, with a Scopus ranking placing it among the top 10% of journals in its fields. Since its inception in 1990, the journal has served as a crucial platform for researchers and clinicians alike, disseminating groundbreaking findings that advance our understanding of brain diseases and injuries. Through its dedication to publishing high-quality, innovative research, BRAIN PATHOLOGY plays a vital role in shaping the future of brain pathology research. While it does not currently offer open access, articles can be accessed through institutional subscriptions. Researchers, professionals, and students are encouraged to contribute to and engage with this esteemed publication to foster knowledge and collaboration within this dynamic field.